Bacteriophage Therapy Summit 2026

The 8th edition of the Hanson Wade Bacteriophage Therapy Summit will be held in London, UK from Tuesday 24th March till Thursday 26th March 2026.

What is the 8th Bacteriophage Therapy Summit and Why attend?

Step into the next era of bacteriophage therapeutic innovation at the 8th Bacteriophage Therapy Summit 2026! This year’s event brings the global phage community to London, United Kingdom, uniting leading biotech innovators, pharma executives, regulatory experts, academic researchers, and investors for a powerful three‑day program dedicated to advancing regulatory‑ready, precision phage therapies.

As the only industry‑led, industry‑dedicated global platform focused on bringing phage therapeutics from bench to bedside, the 2026 summit is designed to accelerate the translation of phage science into commercially scalable, clinically validated antibacterial solutions. With regulatory pathways becoming clearer and multiple phage programs entering late‑stage clinical development, 2026 marks a pivotal year for the field.

Over 3 days, attendees will immerse themselves in cutting‑edge data, investment insights, manufacturing solutions, and translational frameworks shaping the future of phage-based medicine.

The 8th Bacteriophage Therapy Summit will deep‑dive into:

• Navigating regulatory & investment pathways: Explore how innovators are overcoming approval and funding barriers to bring phage therapies to market, supported by insights from leading organizations shaping the regulatory and commercial landscape.
• Showcasing clinical advances from late-stage programs: Hear from companies presenting clinical data that demonstrates phage efficacy in treating antibiotic‑resistant infections, with speakers from Armata Pharmaceuticals, Intralytix, NexaBiome, and others.
• Scaling GMP manufacturing & industrial production: Dive into strategies for producing stable, reproducible, and regulatory‑compliant phage products at clinical and commercial scale.
• Precision engineering & technology-driven discovery: Learn how emerging tools, including genomics, bioengineering, and algorithmic approaches are reshaping phage selection, optimisation, and delivery at companies across the UK, EU, and US.
• Developing broad-spectrum & tailored phage solutions: Understand how biotech innovators are designing targeted phage cocktails and evolving frameworks to address a wide range of resistant pathogens in human and non‑human health settings.

Who will be at the 8th Bacteriophage Therapy Summit?

The summit will gather C‑suite executives, CSOs, directors, heads, managers, professors, researchers, and scientists from across the phage ecosystem, including drug developers, academic organisations, policymakers, and service providers.

Agenda for the 8th Bacteriophage Therapy Summit 2026

Tuesday 24th March 2026

Pre-conference Workshop

Wednesday 25th March 2026

Danish Malik Professor of Industrial Biotechnology CREST at Loughborough University – Designing Scalable, Cost-Effective Manufacturing Platforms to Advance Phage Therapeutics Toward the Clinic

Danish Malik Professor of Industrial Biotechnology CREST at Loughborough University, Gregorio Iraola CEO at Kinzbio, and Sofia Corte-Real Deputy CEO at TechnoPhage SA – Overcoming Scale-Up Bottlenecks While Protecting Product Consistency to Optimise Commercial Viability, Scalability, & Regulatory Acceptance

Carmen Coxon Principal Scientist & MHRA‑GAMRIF Team Lead at Medicines & Healthcare Products Regulatory Agency (MHRA) – Charting Realistic Regulatory Pathways for Phage Development in a Changing Global Landscape

Alexander Sulakvelidze President & CEO at Intralytix, Inc. – From Discovery to Clinic and Everything in Between: Intralytix’s Path to Phage Therapies and Microbiome Modulation

Mimi Yen CEO at PhagePro – Defining the Pathway for Phage Therapeutics in Global Health: Translating Outbreak Prevention from Concept to Clinic

William Marsh CEO at Phagefarm – Translating Phage Science into Consumer Products to Drive Scalable, Regulated & Profitable Innovation

Ben Swift Lead Scientist at Carus Animal Health – Harnessing Phages to Modulate Rumen Microbiomes for Methane Reduction

Matthew Tebeau CEO at Phagelux AgriHealth – Unlocking Sustainable Agricultural Growth Through Phage Innovation to Deliver Proven ROI & Long-Term Adoption

Subhendu Basu CEO at Telum Therapeutics – Reviving Confidence in Lysins Through Next-Generation Engineering to Deliver Real Therapies Against Resistant Infections

Jonas Hink Chief Medical Officer at SNIPR Biome – Advancing Engineered Phages Toward Clinical Reality

Matt Cummings VP of UK Operations at Precisio Biotix Therapeutics – Translating Novel Modalities from Concept to Clinic to Strengthen Phage’s Therapeutic Future

Thursday 26th March 2026

Jason Clark CEO at NexaBiome – Establishing a Clear & Predictable UK Regulatory Pathway to Accelerate Clinical Phage Access

Carmen Coxon Principal Scientist & MHRA‑GAMRIF Team Lead at Medicines & Healthcare Products Regulatory Agency (MHRA), Francesca Hodges Innovation Lead at Future Medicines, Medicines Discovery & Medicines Manufacturing, Innovate UK, Catherine E.D. Rees Professor of Microbiology & Division Head at University of Nottingham, and Jason Clark CEO at NexaBiome – Building a Unified Global Framework to Enable Scalable Phage Development, Investment Confidence & Market Access

Carmen Coxon Principal Scientist & MHRA‑GAMRIF Team Lead at Medicines & Healthcare Products Regulatory Agency (MHRA) – Charting Realistic Regulatory Pathways for Phage Development in a Changing Global Landscape

Raquel Rodríguez Alonso Policy Officer, DG HERA at European Commission – Strengthening Europe’s Innovation & Preparedness Frameworks to Tackle Emerging Antimicrobial Threats

Colin Brown Head of Antimicrobial Resistance & Healthcare Associated Infections and Deputy Director: Epidemic & Emerging Infections at UK Health Security Agency (UKHSA) & Mark Sutton Professor for Antimicrobial Therapy & Scientific Leader, UKHSA at Kings College University – Translating Phage Promise into Practice: Building the Evidence, Infrastructure & Oversight for Clinical Adoption

Jean‑Paul Pirnay Head of Laboratory at Queen Astrid Military Hospital LabMCT – Proving the Potential: What Happens When Phage Therapy Reaches the Bedside

Ryszard Międzybrodzki Head of Lab at Hirszfeld Institute of Immunology and Experimental Therapy – Beyond Bacterial Lysis: Uncovering the Immunological Dimensions of Phage Therapy

Antonia Scobie Consultant & Research Lead, Bone Infection Unit at NHS – Integrating Phage Therapy into Bone & Joint Infection Management: Clinical Insights from the UK Working Group

Catherine E.D. Rees Professor of Microbiology & Division Head at University of Nottingham – Leveraging Phage for Diagnostic Innovation: Lessons from Translating Lab Research into Commercial Reality

Stephanie Lesage Co‑founder & CEO at OSPT Ltd – Reimagining Infection Prevention with Phage-Enhanced Medical Devices to Reduce Cardio Vascular-Associated Infections & Beyond

Amanda Burkardt CEO at Phiogen Pharma – Rewriting Chronic Disease with Dual-Action Phage Therapeutics

View past events by Hanson Wade